{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T10:58:28Z","timestamp":1648551508546},"reference-count":23,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T00:00:00Z","timestamp":1458000000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir. j. psychol. Med."],"published-print":{"date-parts":[[2017,3]]},"abstract":"<jats:sec id=\"S0790966716000148_abs1\" sec-type=\"general\"><jats:title>Aims and methods<\/jats:title><jats:p>Antipsychotics have proven benefits in children and adolescents with autism spectrum disorders. However, notwithstanding some therapeutic benefits significant side effects are associated with the use of antipsychotics, such as hyperprolactinaemia. We completed an audit cycle between April 2013 and December 2013 to evaluate the practice in the Beechpark Autism Service with respect to monitoring and managing hyperprolactinaemia in children and adolescents prescribed antipsychotics. The re-audit assessed whether the recommended guidelines and changes had been implemented. The National Institute for Health and Care Excellence guidelines were used as a gold standard for this audit.<\/jats:p><\/jats:sec><jats:sec id=\"S0790966716000148_abs2\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Basal determinations of serum prolactin improved significantly at the end of the audit cycle (28.6% <jats:italic>v<\/jats:italic>. 57%) with slight improvement in six monthly repeat prolactin monitoring (28.6% <jats:italic>v<\/jats:italic>. 39.1%) showing some change in clinical practice. However, there was minimal improvement in managing hyperprolactinaemia (0% <jats:italic>v<\/jats:italic>. 12.5%).<\/jats:p><\/jats:sec><jats:sec id=\"S0790966716000148_abs3\" sec-type=\"general\"><jats:title>Clinical implication<\/jats:title><jats:p>There is growing awareness about hyperprolactinaemia associated with the use of antipsychotic medication in children and adolescents and the long-term effects. Clear documented guidelines will help increase and improve the monitoring and management of hyperprolactinaemia in these groups of patients. However, more needs to be done in improving the practice of monitoring and managing hyperprolactinaemia in children and adolescent prescribed antipsychotic medication giving the documented long-term effects.<\/jats:p><\/jats:sec>","DOI":"10.1017\/ipm.2016.14","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T04:17:55Z","timestamp":1458015475000},"page":"45-51","source":"Crossref","is-referenced-by-count":0,"title":["Monitoring of prolactin levels in children and adolescents prescribed antipsychotic medication: a complete audit cycle"],"prefix":"10.1017","volume":"34","author":[{"given":"E.","family":"Uduehi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Alugo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"56","published-online":{"date-parts":[[2016,3,15]]},"reference":[{"key":"S0790966716000148_ref13","unstructured":"Oxford Health NHS Foundation Trust (2012). Antipsychotic induced hyperprolactinaemia: trust guidelines for identification, monitoring, and management (http:\/\/www.seqo.nhs.uk\/buckinghamshire\/shared\/images\/files\/ccg-prescribing\/Clinical\/04.%20Central%20Nervous%20System\/Mental%20Health\/Antipsychotic%20induced%20hyperprolactinaemia.pdf). Accessed 5 May 2014."},{"key":"S0790966716000148_ref5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-11-0076"},{"key":"S0790966716000148_ref4","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/502697"},{"key":"S0790966716000148_ref22","first-page":"161","article-title":"Macroprolactin; a frequent cause of misdiagnosed hyperprolactinaemia in clinical practice","volume":"11","author":"Vaishya","year":"2010","journal-title":"Journal of Reproduction and Infertility"},{"key":"S0790966716000148_ref6","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.1.64"},{"key":"S0790966716000148_ref16","unstructured":"Sussex Partnership NHS Foundation Trust (2014). Guidance for the treatment of antipsychotic induced hyperprolactinaemia in adults (http:\/\/www.sussexpartnership.nhs.uk\/component\/jdownloads\/finish\/2030\/8963?Itemid=0). Accessed 5 May 2014."},{"key":"S0790966716000148_ref17","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.748"},{"key":"S0790966716000148_ref19","unstructured":"Taylor D , Paton C , Kapur S (2012). The Maudsley Prescribing Guidelines, 11th Edition. Wiley Blackwell: London."},{"key":"S0790966716000148_ref2","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2005.15.869"},{"key":"S0790966716000148_ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094112"},{"key":"S0790966716000148_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2006.08.009"},{"key":"S0790966716000148_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2013.04.015"},{"key":"S0790966716000148_ref12","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2006.17303"},{"key":"S0790966716000148_ref20","unstructured":"Tee Esk , Weer Valleys NHS Foundation Trust (2013). Guidelines for the management of hyperprolactinaemia in patients receiving antipsychotics (http:\/\/www.tewv.nhs.uk\/Global\/Policies%20and%20Procedures\/Pharmacy\/PHARM-0032-v3%20Hyperprolactinaemia%20Guidelines.pdf). Accessed 5 May 2014."},{"key":"S0790966716000148_ref7","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.08m04595gre"},{"key":"S0790966716000148_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"S0790966716000148_ref21","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Therapeutics and Clinical Risk Management"},{"key":"S0790966716000148_ref9","first-page":"851","article-title":"Management of psychotropic-induced hyperprolactinaemia","volume":"11","author":"Marken","year":"1992","journal-title":"Clinical Pharmacy"},{"key":"S0790966716000148_ref14","doi-asserted-by":"publisher","DOI":"10.1186\/1687-9856-2010-159402"},{"key":"S0790966716000148_ref10","unstructured":"National Collaborating Centre for Mental Health (2013). Psychosis and Schizophrenia in Children and Young People (Clinical Guideline No. 155). National Institute for Health and Clinical Excellence (NICE), London: 51 pp."},{"key":"S0790966716000148_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2011.11.010"},{"key":"S0790966716000148_ref1","first-page":"64","article-title":"Hyperprolactinemia: monitoring children on long-term risperidone","volume":"7","author":"Ali","year":"2008","journal-title":"Current Psychiatry"},{"key":"S0790966716000148_ref11","unstructured":"North Hampshire Healthcare NHS Foundation Trust (2013). Guidelines for the management of antipsychotic induced hyperprolactinaemia (http:\/\/www.nht.nhs.uk\/mediaFiles\/downloads\/102018381\/MMG007%20Management%20of%20antipsychotic-induced%20hyperprolactinaemia%20-%20_Sept13-Sept15_.pdf). Accessed 19 September 2015."}],"container-title":["Irish Journal of Psychological Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0790966716000148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T22:24:00Z","timestamp":1555539840000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0790966716000148\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,15]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0790966716000148"],"URL":"https:\/\/doi.org\/10.1017\/ipm.2016.14","relation":{},"ISSN":["0790-9667","2051-6967"],"issn-type":[{"value":"0790-9667","type":"print"},{"value":"2051-6967","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,15]]}}}